- SEC Filing
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 3/10/2026 | $180.00 | Buy | Jefferies | |
| 2/20/2026 | $155.00 | Equal Weight | Barclays | |
| 2/11/2026 | $140.00 → $170.00 | Buy | Needham | |
| 1/7/2026 | $145.00 | Buy | UBS | |
| 11/24/2025 | $140.00 | Buy | Truist | |
| 11/13/2025 | $140.00 | Sector Outperform | Scotiabank | |
| 8/19/2025 | $128.00 | Neutral → Outperform | Daiwa Securities | |
| 8/8/2025 | $127.00 | Hold → Buy | Truist |
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
Jefferies initiated coverage of Gilead Sciences with a rating of Buy and set a new price target of $180.00
Barclays initiated coverage of Gilead Sciences with a rating of Equal Weight and set a new price target of $155.00
Needham reiterated coverage of Gilead Sciences with a rating of Buy and set a new price target of $170.00 from $140.00 previously
– Grants to Strengthen Prevention Models and Local Systems of Care Nationwide – Gilead Foundation today announced a $12 million investment in 33 community‑based organizations across 14 states and the District of Columbia through its Community Health Worker (CHW) Comprehensive HIV Prevention Initiative. This two‑year effort expands CHW‑led prevention models that strengthen knowledge, care navigation, and access to services for communities disproportionately affected by HIV. "Community health workers are often the first and most trusted point of connection for people seeking information, support and care," said Keeley Cain Wettan, Executive Vice President, General Counsel, Legal and Compl
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will participate in a fireside chat during the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m. ET. A live webcast can be accessed under "Events & Presentations" in the Investors & Media section of the Xilio Therapeutics website at ir.xiliotx.com. A replay of the webcast will be archived on the website for 30 days following the presentation. About Xilio Therapeutics Xilio Therapeutics is a clinica
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective March 1, 2026, the company granted non-qualified stock options to purchase 50,050 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.5283 per share, which is equal to the closing price of the company's common stock on February 27, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
10-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218926462/en/Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Par
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases. "Da
– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the Safety and Efficacy Profile of Twice-Yearly Lenacapavir for HIV Prevention – Gilead Sciences, Inc. (NASDAQ:GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities af
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 3.8% in the company's quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 13, 2026. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi
Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over-Year to $14.3 billion for Full Year 2025 Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the fourth quarter and full year 2025. "Our fourth quarter and full-year results close out a very strong year for Gilead overall, including the successful U.S. launch of Yeztugo, the world's first twice-yearly HIV prevention therapy, and continued growth for Biktarvy and Descovy," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "In 2026, our potential new launches include two cancer therapies and an additional HIV
SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)